Peer-reviewedLicence not statedJournal of Hepatology
Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD
Related
- A Systematic Review of Metachromatic Leukodystrophy Newborn Screening: Transitioning from Pilot Studies to the Real World.
- Cost-utility analysis of deep learning-based opportunistic osteoporosis screening using chest radiographs: implications of diagnostic thresholds and confirmatory testing.
- Performance of protein panels is inflated across many biomarker studies
- Bone marrow kinase X-linked in pulmonary diseases: pathogenic gene, diagnostic biomarker, and treatment target—a narrative review
- Surgical resection for indeterminate pulmonary nodules in patients with prior breast cancer: diagnostic value and biomarker reassessment
BibTeX
@article{ratziu2026confirmatory,
title = {{Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD}},
author = {Vlad Ratziu and Jérôme Boursier and Victor de Ledinghen and Rodolphe Anty and Charlotte Costentin and Christophe Bureau},
journal = {Journal of Hepatology},
year = {2026},
month = oct,
doi = {10.1016/j.jhep.2023.07.017},
url = {https://hal.science/hal-05840310v1},
}
RIS
TY - JOUR
TI - Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD
AU - Vlad Ratziu
AU - Jérôme Boursier
AU - Victor de Ledinghen
AU - Rodolphe Anty
AU - Charlotte Costentin
AU - Christophe Bureau
PY - 2026
DA - 2026/10/27
JO - Journal of Hepatology
DO - 10.1016/j.jhep.2023.07.017
UR - https://hal.science/hal-05840310v1
SN - 0168-8278
SN - 1600-0641
ER -